Classical Hodgkin lymphoma (cHL) is an atypical germinal center derived B-cell lymphoma (gcdBCL) that has lost its B-cell identity. 1 Some reports have suggested that epigenetic modifications are involved in this cHL-associated B-cell reprogramming. 2, 3 Here, aiming at investigating DNA methylation patterns on a more genome-wide level, we have performed 27K BeadArray analysis 4 in five cHL cell lines. Owing to the low numbers of tumor cells in primary cHL biopsies (B1%), our microarray analyses were restricted to cHL cell lines, which represent widely used models to study this lymphoma. The results from cHL cell lines were compared with those of 20 previously analysed gcdBCL diagnosed as Burkitt lymphomas and diffuse large B-cell lymphomas 5 and three normal B-cell (NBC) populations 6 (for details see Supplementary Information). Results of the BeadArray analysis were exemplary validated by bisulfite pyrosequencing (Supplementary Figure S2) .
After filtering sex chromosome-specific and low-quality CpGs (outlined in the Supplementary Information), a total of 24 312 autosomal CpGs corresponding to 13 088 genes entered the statistical analyses. We initially classified these CpGs according to their methylation status in NBC. We As we aimed at identifying genes clearly hyper-or hypomethylated in lymphomas as compared with NBCs, this third group was not used for further analyses.
We then identified CpGs showing differential methylation between B-cell lymphoma, that is, joint cHL and gcdBCL, as compared with NBCs. Applying the criteria detailed in the Supplementary Information, we observed a total of 383 CpGs (329 genes) commonly hypermethylated in cHL, gcdBCL cell lines and primary gcdBCL as compared with NBC ( Figure 1a) . From now on, this group of genes will be called hypermethylated in cHL/gcdBCL (Hmet-cHL/gcdBCL). These genes were mostly enriched for gene ontology (GO) terms associated with development and morphogenesis (Po0.001), regulation of the canonical Wnt receptor signaling pathway (Po0.001) and regulation of adenylate cyclase activity (Po0.001) ( Table 1,  Supplementary Figure S5 and Supplementary Table S3) .
As the main goal of the present study was to characterize the specific changes in the methylome of cHL as compared with gcdBCL, we analyzed cHL vs NBC and gcdBCL, and gcdBCL vs NBC and cHL. By this approach, we identified a total of 247 CpGs (209 genes) that were exclusively hypermethylated in cHL but not in gcdBCL or controls (from now on called Hmet-cHL) ( Figure 1b ) and 12 CpGs (9 genes) that were hypermethylated only in gcdBCL but not in cHL or controls (Figure 1c) . Genes Hmet-cHL were enriched for immune system functions like positive regulation of B-cell activation (Po0.001) and regulation of T-cell differentiation (Po0.001) ( Table 1 , Supplementary Figure S6 and Supplementary Table S4 ). Also, if the GO analysis is restricted to those genes silenced de novo in cHL (that is, expressed in NBCs and silenced in cHL), the B-cell program was also identified (Supplementary Figure S7 and Supplementary  Table S5 ). These findings indicate that genes Hmet-cHL target the B-cell program.
Lymphoma-associated hypomethylation was a much less common event. Comparing lymphomas (that is, joint cHL and gcdBCL) to NBC, only 10 CpGs (10 genes) were identified as hypomethylated in the lymphoma samples. We also detected 22 CpGs (22 genes) that were hypomethylated only in cHL and one CpG only in gcdBCL as compared with NBC. Lists of differentially methylated genes are provided in and Supplementary  Table S2 .
In order to study the expression pattern of differentially methylated genes, we analyzed previously published microarray-based expression profiles of normal germinal center B cells, cHL cell lines as well as gcdBCL cell lines and primary cases. 7 As DNA methylation has been associated with gene silencing, we computed the percentage of absent detection calls (suggesting complete silencing of the respective genes) of hypermethylated genes in lymphomas versus all the genes analyzed with the methylation array. As shown in Figure 2a , approximately half of all the genes studied with the methylation array were not expressed at detectable levels in NBC, cHL and gcdBCL. As expected, genes Hmet-cHL/gcdBCL were frequently silenced in these entities (87% in cHL and 92% in gcdBCL). Interestingly, in spite of the fact that these genes were unmethylated in NBC, they showed similar frequency of absent calls (92%) in NBC. In contrast, genes Hmet-cHL showed a higher percentage of absent calls (that is, not expressed) in cHL (62%) than in NBCs (32%) and gcdBCL (40%). Additionally, we compared whether genes silenced de novo in cHL as compared with gcdBCL showed different level of silencing in BL and DLBCL separately. We did not observe any difference between BL and DLBCL (Supplementary Figure S4) . Altogether, these results indicate that, in general, the expression of genes de novo methylated in cHL and gcdBCL does not change between NBCs and these lymphoma entities. In contrast, de novo DNA methylation only in cHL is frequently associated with de novo gene silencing. Together with the fact that genes Hmet-cHL mostly target the B-cell program, this finding indicates that DNA methylation-associated silencing is related with disruption of the B-cell signature in cHL.
To investigate whether the promoter regions of differentially methylated genes showed a different CpG density, we classified the genes into those with high CpG promoters (HCP), intermediate CpG promoters (ICP) and low CpG promoters (LCP) CpG content using a published classification system. 8 As compared with all the genes studied with the array, genes Hmet-cHL/gcdBCL were enriched for promoters with a high CpG content (80% vs 62%, Po0.001) (Figure 2c ). In contrast, the proportion of HCP in genes Hmet-cHL was significantly lower than in all the genes studied (49% vs 62%, Po0.01) (Figure 2c ).
As hypermethylation in cHL was associated with de novo gene silencing, we investigated whether this phenomenon was related to genes containing HCP or LCP promoters. We first did a general analysis and observed that genes HmetcHL with HCP promoters only show a slight increase of gene silencing (40% absent calls in normal germinal center B cells vs 55% in cHL, respectively). Interestingly, LCP promoters are clearly associated with de novo silencing (24% absent calls in normal germinal center B cells vs 79% in cHL, respectively) ( Figure 2b ). We subsequently restricted the analysis only to the fraction of genes silenced de novo in cHL (that is, present in NBC and absent in cHL). Using this approach, we observed that 62.1% of the genes showed LCP and 37.9% HCP promoters. The fact that de novo epigenetic silencing in cHL targets mostly LCP promoters is intriguing, as DNA hypermethylation and silencing in cancer is widely reported to affect genes with promoters containing dense CpG islands (that is, HCP promoters). 9 Recently, it has been observed that hypermethylation of genes in solid and hematological tumors seems to be mostly mediated by recruitment of DNA methyltransferases to genes targeted by EZH2, a member of the polycomb repressive complex 2 (PRC2), in embryonic stem cells (ESC). 6, 10 A recent study has demonstrated that EZH2 binding is not restricted to ESCs, and that ESCs and centroblasts (CBs) share B45% of the EZH2 targets. 11 Here, we investigated whether genes Hmet-cHL/gcdBCL are enriched for EZH2 or 3mK27H3 targets in ESCs and/or normal CBs. 11, 12 As shown in Figure 2d , 42% of the genes Hmet-cHL/gcdBCL are EZH2/3mK27H3 targets shared in ESC and CBs. Compared with the 10% of EZH2/3mK27H3 targets in all the genes analyzed in the array, this enrichment was highly significant (odds ratio (OR) ¼ 6.6, Po0.001). Most interestingly, the enrichment of EZH2/3mK27H3 targets in ESC and CBs among genes Hmet-cHL was only 3%, which is significantly reduced as compared with all studied genes (OR ¼ 0.3, Po0.01). A similar phenomenon was observed for EZH2/3mK27H3 targets only in CBs, but the effect was not so marked (Figure 2d) .
These results indicate that in contrast to genes Hmet-cHL/ gcdBCL, most Hmet-cHL genes do not seem to be predisposed to acquire aberrant DNA methylation by PRC2 binding. This finding suggests that cHL-specific hypermethylation might not be mediated by PRC2 but by an alternative, yet unknown, mechanism. However, for example, an HRS-specific de novo binding of EZH2 to genes Hmet-cHL cannot be ruled out.
An additional fact highlighting the importance of EZH2 in lymphomagenesis is that this gene is recurrently mutated (Tyr641) in some B-cell lymphomas. 13 Here, we report for the first time that a mutation at the Tyr641 residue of EZH2 is also present in cHL (Supplementary Figure S8) , although the functional consequences of this genetic alteration in cHL remain to be explored.
In summary, our study provides a genome-wide DNA methylation map of cHL as compared with other gcdBCLs. In particular, we show that as compared with genes Hmet-cHL/ gcdBCL, genes hypermethylated only in cHL are enriched for functions silenced in cHL, like regulation of B-cell or T-cell activation. Also, these genes Hmet-cHL display specific features atypical for hypermethylated genes, including the frequent occurrence of de novo silencing of genes with promoters containing low CpG content and the lack of enrichment for EZH2 targets in ESCs or normal CBs.
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